Lantern is billed as an AI-driven revenue tool aimed at accelerating revenue workflows, claiming 19% increase in average deal size through timed upsell outreach. The Champion Agent monitors personnel shifts across the customer base to automate outreach for certain teams. Lantern Pharma reports progress in 2026, reducing R&D spend by 47% while progressing clinical programs, launching an AI platform with Zeta.ai and expanding an AI Center of Excellence in India. These developments illustrate Lantern's growth into AI-powered drug discovery partnerships, supported by ongoing financing to fuel expansion.
Sources
news
www.newswire.caDisciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing of up to $9.25 Million
natlawreview.comLantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform...
www.innovationopenlab.comBrowse, deploy, and customize AI agents that automate every critical revenue function—from champion tracking to intent monitoring, all available in minutes.
withlantern.comlantern News and Updates from The Economictimes.com
economictimes.indiatimes.comDisciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing of up to $9.25 Million Q1 net loss reduced 27% year-over-year while progressing multiple...
www.pharmiweb.com